Related Experiment Video

Updated: Feb 6, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.7K

A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer

Gururaj Shivange1, Karol Urbanek1, Piotr Przanowski2

  • 1Laboratory of Novel Biologics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA; UVA Cancer Center, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.

Cancer Cell
|August 15, 2018
PubMed

Insights

This study introduces a novel bispecific antibody for ovarian cancer (OvCa) that enhances tumor cell killing. By targeting folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5), it achieves superior, tumor-specific apoptosis compared to current treatments.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Therapeutic antibodies for ovarian cancer (OvCa) show limited efficacy due to poor tumor-specific cytotoxicity.
  • Existing treatments often fail to achieve sufficient tumor cell killing for clinical success.

Purpose of the Study:

  • To develop a novel bispecific antibody strategy for enhanced ovarian cancer treatment.
  • To improve tumor-specific antibody-dependent cellular cytotoxicity in ovarian cancer.

Main Methods:

  • Designed a bispecific antibody targeting folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5).
  • Investigated the antibody's ability to induce 'cis' and 'trans' cytotoxicity.
  • Utilized FOLR1 as an anchor to cluster the antibody on tumor cells for sustained apoptosis.

Main Results:

  • The bispecific antibody demonstrated superior selectivity and efficacy compared to investigational antibodies.
  • FOLR1 anchoring facilitated sustained tumor-specific apoptosis via DR5 signaling.
  • The approach achieved high levels of tumor-specific cell death.

Conclusions:

  • A symbiotic bispecific antibody approach targeting FOLR1 and DR5 offers a promising strategy for ovarian cancer therapy.
  • This method enhances tumor-specific cytotoxicity and apoptosis, potentially leading to a clinically viable treatment for OvCa.
Keywords:
TRAIL-R2antibody therapycancercancer signalingcaspasescell signalingdual-specificity targetingfolate receptor alpha-1ovarian cancertargeted therapies

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence06:25

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence

Published on: February 10, 2023

2.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.0K
Framing Effects03:26

Framing Effects

Information is everywhere and its presentation—such as how and when items are presented—can impact our perceptions and decisions surrounding the info. This broad concept umbrellas framing effects—influences that occur due to the way information is framed in its appearance, whether it’s purely the order or the specific wording of a message. Let’s take a look at numerous ways in which two versions of something can objectively say the same thing, yet we respond in...
8.0K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
574
Buffer Effectiveness02:19

Buffer Effectiveness

Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised.
The buffer capacity is the amount of acid or base that can be added to a given volume...
55.4K